AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34909917
Drug: Oral pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pilocarpine (20 mg daily)
Trial: 33639559
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of feedback and modeling
Trial: 33906609
Drug: Initial heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial heparin dose of 100 U/kg (Warfarin group)
Trial: 33906609
Drug: Initial heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial heparin dose of 110 U/kg (NOAC group)
Trial: 33906609
Drug: Initial heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial heparin dose of 120 U/kg (NOAC group)
Trial: 33906609
Drug: Initial heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial heparin dose of 130 U/kg (NOAC group)
Trial: 32602755
Drug: Topical oxymetazoline
RxNorm normalized name: oxymetazoline Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oxymetazoline (OXZ) 1.5% in liposomal base
Trial: 32602755
Drug: Topical lipogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lipogel (control)
Trial: 33595845
Drug: Benralizumab 30
RxNorm normalized name: benralizumab 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab 30 mg SC
Trial: 33157937
Drug: 8-week mindfulness-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week mindfulness-based cognitive therapy program
Trial: 38858629
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TaU)
Trial: 34764014
Drug: Acupressure at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupressure at the BL67 point for 10 minutes daily for two consecutive weeks
Trial: 35510486
Drug: Imetelstat 9.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imetelstat 9.4 mg/kg administered as an intravenous infusion every 21 days
Trial: 35510486
Drug: Best available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best available therapy, excluding JAK inhibitors
Trial: 33243811
Drug: Individualised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised physical exercise training programmes combined with increased protein intake (IPET+P) receiving 27.5 g protein/day
Trial: 33243811
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care with protein supplementation (UC+P) receiving 27.5 g protein/day
Trial: 35780048
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) plus radical local therapy (RLT)
Trial: 37351372
Drug: Positive airway
RxNorm normalized name: VersaPAP Positive Airway Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive airway pressure (PAP) therapy
Trial: 35190177
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg intravenously on days 1, 15, and 29; n = 23)
Trial: 35190177
Drug: Nivolumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab with ipilimumab (1 mg/kg intravenously on day 1; n = 21)
Trial: 34702332
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (single‐dose muscle relaxant administration at induction)
Trial: 32886321
Drug: Direct Oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct Oral Anticoagulants (DOACs) - Dabigatran (66%), Apixaban (21%), Rivaroxaban (13%); 58% prescribed reduced dose.
Trial: 35562830
Drug: Meridian theory-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meridian theory-based extracorporeal shock wave therapy (ESWT)
Trial: 35562830
Drug: Conventional extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional extracorporeal shock wave therapy (ESWT)
Trial: 33490019
Drug: Per capita
RxNorm normalized name: Lespedeza capitata flowering top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per capita monthly income
Trial: 33676295
Drug: FOLFOXIRI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOXIRI treatment
Trial: 35588050
Drug: Denosumab 120
RxNorm normalized name: DENOSUMAB 120 MG/1.7 ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 120 mg subcutaneously every 4 weeks for 6 cycles
Trial: 35588050
Drug: Nab-paclitaxel 125
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 125 mg/m2 weekly for 12 weeks
Trial: 35588050
Drug: Nab-paclitaxel days
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel days 1 and 8 every 3 weeks for 4 cycles (8 doses)
Trial: 35588050
Drug: Nab-paclitaxel weekly
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel weekly
Trial: 35864302
Drug: Cinnarizine 20
RxNorm normalized name: cinnarizine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine 20 mg and Dimenhydrinate 40 mg
Trial: 35960902
Drug: Rucaparib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib 600 mg twice a day orally
Trial: 32316331
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy group
Trial: 36203323
Drug: Active cTBS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active cTBS treatment
Trial: 36203323
Drug: Sham cTBS
RxNorm normalized name: Syn023 component ctb-011
DrugBank: Zamerovimab (DB17766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham cTBS treatment
Trial: 32096437
Drug: Lomb-Scargle (L-S)
RxNorm normalized name: L-S-Adenosylmethionine
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomb-Scargle (L-S) periodogram
Trial: 32162607
Drug: Mg citrate
RxNorm normalized name: K-Mg Citrate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg citrate (MgC)
Trial: 32162607
Drug: Mg oxide
RxNorm normalized name: citric acid/Mg oxide/Na picosulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg oxide (MgO)
Trial: 33907188
Drug: Duloxetine (serotonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (serotonin and noradrenaline reuptake inhibitor)
Trial: 34910143
Drug: Levonorgestrel (LNG)
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel (LNG) Implant
Trial: 33928827
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy and combined oral contraceptives
Trial: 32384500
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of intravenous dexamethasone and 1 dose of normal saline (Group A)
Trial: 32384500
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of intravenous dexamethasone (Group B)
Trial: 36562419
Drug: Low-dose fenfluramine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fenfluramine
Trial: 32976660
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg prednisolone
Trial: 35196580
Drug: Heating therapy
RxNorm normalized name: MENTHOL 2.8 g in 56 g TOPICAL CREAM [elevate HEATING THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heating therapy
Trial: 35196580
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no heating therapy)
Trial: 35649607
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual Optimised (TAU-O)
Trial: 33448754
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (CG) - only had their symptoms monitored through phone calls, maintaining usual care treatment
Trial: 33706319
Drug: Bridging therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging therapy (BT)
Trial: 35287480
Drug: Yangxin Recipe
RxNorm normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yangxin Recipe (YXR) + conventional western medicine
Trial: 35691324
Drug: ChAdOx1 nCoV‐19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 nCoV‐19 (AZD1222) vaccine, 5 × 10^10 viral particles, two doses
Trial: 35691324
Drug: Capsular group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsular group B meningococcal vaccine (control)
Trial: 33934714
Drug: Levetiracetam (1000–3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (1000–3000 mg)
Trial: 33934714
Drug: Fosphenytoin (22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosphenytoin (22.5 mg/kg)
Trial: 34052232
Drug: IV sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV sildenafil (loading: 0.1 mg/kg over 30 minutes; maintenance: 0.03 mg/kg/h)
Trial: 32240542
Drug: Mobile text
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile text messaging (3 to 5 messages daily for one month)
Trial: 36197388
Drug: Drug use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug use prevention program #TamoJunto2.0
Trial: 32660769
Drug: MSB11455 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSB11455 (6 mg/0.6 mL)
Trial: 32333641
Drug: Neulasta® (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neulasta® (6 mg/0.6 mL)
Trial: 32164428
Drug: Nitroglycerin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin infusion (0.5 mcg/kg/min)
Trial: 32500486
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg once daily plus Metformin 1000 mg once daily for 12 weeks
Trial: 32500486
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg once daily plus placebo for 12 weeks
Trial: 33770125
Drug: History of
RxNorm normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: History of using oral contraceptive pills
Trial: 32198342
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg bolus over 30 min, followed by 1 mg/kg/h continuous infusion for 6 h)
Trial: 39025264
Drug: vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle cream
Trial: 33962592
Drug: CPI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPI treatment combined with SBRT (Arm A)
Trial: 33962592
Drug: CPI monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPI monotherapy (Arm B)
Trial: 32997046
Drug: Post-treatment evaluation
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment evaluation
Trial: 32997046
Drug: POC‐CCA test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POC‐CCA test post-treatment
Trial: 33341955
Drug: Tegoprazan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan (50 mg and 100 mg) coadministered with amoxicillin/clarithromycin (1000/500 mg) for 7 days
Trial: 33341955
Drug: Pantoprazole-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole-based triple therapy
Trial: 38847412
Drug: Rocuronium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.3 mg/kg
Trial: 33413594
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg once daily for 36 months
Trial: 32955410
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy (CC)
Trial: 32955410
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy plus adjuvant chemotherapy (CC + AC)
Trial: 32955410
Drug: Overall comparison
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall comparison of IC, CC, and CC + AC
Trial: 35468847
Drug: Salbutamol (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (single intravenous injection)
Trial: 32521736
Drug: Escitalopram (SSRI),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (SSRI), 6-week treatment
Trial: 32521736
Drug: Placebo, 6-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 6-week treatment
Trial: 34689669
Drug: Non-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment control video
Trial: 33653685
Drug: High oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High oxygen protocol (6-8 L/min by face mask)
Trial: 34734297
Drug: Coated implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated implant (TiNiN)
Trial: 34734297
Drug: Standard implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard implant (CoCr)
Trial: 32235930
Drug: Underfeeding and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Underfeeding and Oral vancomycin
Trial: 35995733
Drug: ACB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACB with 20 mL of 0.5% ropivacaine
Trial: 32581409
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula (HFNC) therapy
Trial: 32229139
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g dark chocolate containing 410 mg of flavanols per day
Trial: 32229139
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g dark chocolate containing 86 mg of flavanols per day
Trial: 35452108
Drug: 8-week weight
RxNorm normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-week weight loss and lifestyle intervention (nutritional behavior change, aerobic exercise, sleep hygiene, alcohol and tobacco cessation) combined with usual care (CPAP therapy)
Trial: 35452108
Drug: usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: usual care (CPAP therapy)
Trial: 35101094
Drug: BioBlock nasal
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BioBlock nasal spray (intervention)
Trial: 35101094
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray (control)
Trial: 35273566
Drug: LT3 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LT3 monotherapy for 12 weeks
Trial: 35273566
Drug: LT4 monotherapy
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LT4 monotherapy for 12 weeks
Trial: 33431075
Drug: Endovascular Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular Therapy (EVT)
Trial: 33250038
Drug: Endovascular Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular Therapy (EVT) with CT selection
Trial: 33250038
Drug: Endovascular Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular Therapy (EVT) with MRI selection
Trial: 35164833
Drug: Dietary advice
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary advice reinforced by weekly supportive phone/email support for 4 weeks.
Trial: 35164833
Drug: Potassium supplement
RxNorm normalized name: Potassium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium supplement prescribed if no increase in potassium intake after 4 weeks.
Trial: 35164833
Drug: Dietary advice
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary advice and potassium supplement.
Trial: 35164833
Drug: Concurrent measurements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent measurements of sodium intake, blood pressure, participant satisfaction, and safety measures.
Trial: 33774529
Drug: Steroid-treated transfers
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-treated transfers
Trial: 32501812
Drug: Prenatal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal treatment (specifics not provided)
Trial: 32264698
Drug: Prothrombin complex
RxNorm normalized name: prothrombin complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prothrombin complex concentrates (PCCs) administered to patients with factor Xa inhibitor-related ICH
Trial: 32340638
Drug: IbET (internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IbET (internet-based extinction therapy)
Trial: 36120805
Drug: Cold Atmospheric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold Atmospheric Plasma (CAP) technology, treated biweekly for five sessions with a follow-up 30 days after final treatment
Trial: 34008703
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia with low-dose morphine (15 mcg/kg)
Trial: 34008703
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia with clonidine (1 mcg/kg)
Trial: 32493459
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of expanded umbilical cord blood cells at a dose of 5 million cells/kg (maximum dose - 500 million cells)
Trial: 34836205
Drug: Xylitol (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol (8 g three times a day for five to seven weeks)
Trial: 34836205
Drug: Erythritol (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythritol (12 g three times a day for five to seven weeks)
Trial: 36099069
Drug: Saxagliptin +
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saxagliptin + Metformin (Saxa+Met)
Trial: 32910141
Drug: Reslizumab (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reslizumab (1.0 mg/kg IV)
Trial: 32910141
Drug: DEC treatment
RxNorm normalized name: Zodryl DEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC treatment
Trial: 34922447
Drug: Pragmatic combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pragmatic combination of behavioural science and evidence-based techniques in study invitation letter
Trial: 35573797
Drug: Risk score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk score based on clinical factors and lymphocyte subtyping including CD8+ T-cell count ≤143 cells/mm3, high-dose corticosteroids (≥50 mg prednisolone equivalent), carbapenem/tigecycline, APACHE II score ≥15, (1,3)-β-D-glucan positivity, emergency gastrointestinal/hepatobiliary surgery.
Trial: 32799994
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy interventions
Trial: 34137783
Drug: Chemoendocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoendocrine therapy
Trial: 35487873
Drug: HLA-G +3142GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLA-G +3142GG genotype in alloimmunized patients with antibodies against Rh and Kell antigens
Trial: 35487873
Drug: HLA-G +14
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HLA-G +14 bp Ins/Del and +3142 C>G variations
Trial: 36680919
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg DHA
Trial: 32698912
Drug: Calanus finmarchicus
RxNorm normalized name: calamus oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calanus finmarchicus oil (CO) 2g daily providing 124 mg stearidonic acid, 109 mg EPA, and 87 mg DHA
Trial: 32470710
Drug: pegylated interferon-alfa2b
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pegylated interferon-alfa2b (PEG-IFNα-2b) at 3 μg/kg/week subcutaneously for 2 years